In Vitro Activity of New β-Lactamase Inhibitor Combinations against bla(NDM), bla(KPC), and ESBL-Producing Enterobacteriales Uropathogens

Antibiotic resistance in uropathogens has increased substantially and severely affected treatment of urinary tract infections (UTIs). Lately, some new formulations, including meropenem/vaborbactam (MEV), ceftazidime/avibactam (CZA), and ceftolozane/tazobactam (C/T) have been introduced to treat infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Razaq, Lubna, Uddin, Fakhur, Ali, Shahzad, Abbasi, Shah Muhammad, Sohail, Muhammad, Yousif, Nabila E., Abo-Dief, Hala M., El-Bahy, Zeinhom M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604030/
https://www.ncbi.nlm.nih.gov/pubmed/37887182
http://dx.doi.org/10.3390/antibiotics12101481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604030/
https://www.ncbi.nlm.nih.gov/pubmed/37887182
http://dx.doi.org/10.3390/antibiotics12101481

Ejemplares similares